Pine Capital Group Limited is a Life Sciences company, engaged in the research, development and commercialisation of cutting-edge technologies to improve and enhance the Quality of Life.
Its current focus includes transdermal drug delivery systems and specialised cosmetic products for the pharmaceutical and cosmeceutical industries. Transcu's transdermal drug delivery technologies allow the local and systemic delivery of drugs through the skin into the body. This innovative, pain-free, non-invasive method can be customised for a wide variety of medical, pharmaceutical and cosmeceutical applications, as an alternative to injections, oral pills and other drug delivery methods such as transmucosal and inhalation.
As a knowledge-based company, it holds patents for three device inventions and has over 500 live filings for patents applications and formulations worldwide.
The company has already succeeded in generating revenues from licensing its proprietary technologies to strategic business partners and anticipates sustainable revenues from manufacturing, distribution and sale of end-products using its proprietary technologies.
|Full Name||Pine Capital Group Limited||Stock No||ADJ|
|Exchange||Singapore Exchange (SGX)||Board||Main board|
|Exchange Sector||Services||Sub Sector||1|
|Par Value (SGD)||0.0000||Issued Shares (Mil)||1966.6740|
|Paid-Up Cap. (SGD Mil)||14.4760||Market Capitalization (Mil)||3.9333|
|Share Price (SGD)|
|Share Price Performance(%)|
|100-day Average Daily Volume ('000)||15,981.97|
|Technical Indicators-A shapshot|
|100-day Moving average||0.00|